Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Penson

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Quality of life after breast cancer diagnosis and survivalMeira Epplein, Ying Zheng, Wei Zheng, et al.
The Lancet. Oncology|February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trialBertrand Tombal, Fred Saad, David Penson, et al.
Urologic Oncology|October 3, 2021
Out-of-pocket costs for commercially insured patients with localized prostate cancerChristopher J D Wallis, Daniel D Joyce, Zachary Klaassen, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|May 22, 2002
The development of a telemedical cancer center within the Veterans Affairs Health Care System: a report of preliminary clinical resultsKevin G Billingsley, David L Schwartz, Susan Lentz, et al.
Future Oncology (London, England)|October 13, 2022
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and regionUgo De Giorgi, Maha Hussain, Neal Shore, et al.
Health Education Research|April 6, 2017
Physicians' perspectives on the informational needs of low-risk prostate cancer patientsCharlotte J Hagerman, Paula G Bellini, Kim M Davis, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 19, 2012
Canadian Consensus Conference: The FDA decision on the use of 5ARIsLaurence Klotz, Michael Chetner, Joseph Chin, et al.
Archives of Internal Medicine|January 13, 2006
The effectiveness of screening for prostate cancer: a nested case-control studyJohn Concato, Carolyn K Wells, Ralph I Horwitz, et al.
Urology|March 12, 2026
Patient-reported psychological and prostate cancer-specific functional outcomes among men with low-risk prostate cancer two years after diagnosis: The PREPARE prospective cohort studyKimberly M Davis, George Luta, Richard M Hoffman, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Quality of life after breast cancer diagnosis and survivalMeira Epplein, Ying Zheng, Wei Zheng, et al.
The Lancet. Oncology|February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trialBertrand Tombal, Fred Saad, David Penson, et al.
Urologic Oncology|October 3, 2021
Out-of-pocket costs for commercially insured patients with localized prostate cancerChristopher J D Wallis, Daniel D Joyce, Zachary Klaassen, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|May 22, 2002
The development of a telemedical cancer center within the Veterans Affairs Health Care System: a report of preliminary clinical resultsKevin G Billingsley, David L Schwartz, Susan Lentz, et al.
Future Oncology (London, England)|October 13, 2022
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
European Journal of Cancer (Oxford, England : 1990)|November 16, 2021
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and regionUgo De Giorgi, Maha Hussain, Neal Shore, et al.
Health Education Research|April 6, 2017
Physicians' perspectives on the informational needs of low-risk prostate cancer patientsCharlotte J Hagerman, Paula G Bellini, Kim M Davis, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 19, 2012
Canadian Consensus Conference: The FDA decision on the use of 5ARIsLaurence Klotz, Michael Chetner, Joseph Chin, et al.
Archives of Internal Medicine|January 13, 2006
The effectiveness of screening for prostate cancer: a nested case-control studyJohn Concato, Carolyn K Wells, Ralph I Horwitz, et al.
Urology|March 12, 2026
Patient-reported psychological and prostate cancer-specific functional outcomes among men with low-risk prostate cancer two years after diagnosis: The PREPARE prospective cohort studyKimberly M Davis, George Luta, Richard M Hoffman, et al.
Pageof 4